Publications by authors named "Yi di Sun"
Article Synopsis
- Intratumoral immune status plays a crucial role in how patients with intrahepatic cholangiocarcinoma respond to therapy, especially with a combination of gemcitabine, oxaliplatin, lenvatinib, and anti-PD1 antibody.
- High levels of certain CD8 T-cell markers (GZMB and proliferating CD8) and low levels of Macro CD5L predict better therapeutic responses, while shifts in T-cell markers indicate varying response levels.
- The study also suggests that using anti-CTLA4 antibody can counteract therapy resistance caused by immune exhaustion, paving the way for more effective cancer treatments based on immune profiling.
Pan-cancer network disorders revealed by overall and local signaling entropy.
J Mol Cell Biol
December 2021
Tumor development is a process involving loss of the differentiation phenotype and acquisition of stem-like characteristics, which is driven by intracellular rewiring of signaling network. The measurement of network reprogramming and disorder would be challenging due to the complexity and heterogeneity of tumors. Here, we proposed signaling entropy (SR) to assess the degree of tumor network disorder.
View Article and Find Full Text PDFArticle Synopsis
- The study analyzes genomics, proteomics, and phosphoproteomics of 480 clinical samples from 146 colorectal cancer patients, highlighting differences between metastatic CRC (mCRC) and non-metastatic cases.
- It identifies three distinct CRC subtypes, with proteomic and phosphoproteomic profiles able to predict clinical outcomes and differentiate metastatic tumors from primary ones.
- The findings suggest that while genetic profiles are similar between primary and metastatic tissues, there is significant proteomic diversity, and personalized drug responses can be anticipated based on kinase network analyses, offering insights for clinical applications.
: Triple-negative breast cancer (TNBC) is a subtype of breast cancer with stronger invasive capacity. For the operation strategies of early staged (stage I and stage II) TNBC patients, BCS plus radiotherapy (BCS+RT), mastectomy only (MRM only) or MRM plus radiotherapy (MRM+RT) is feasible, but no clear conclusion has been made on the choice of these treatments. : The early staged TNBC patients (stage I and stage II) from the Surveillance, Epidemiology and End Results (SEER) program database between 1973 and 2014 were included in the study.
View Article and Find Full Text PDF